Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; P… Read more
Nektar Therapeutics (NKTR) - Total Liabilities
Latest total liabilities as of September 2025: $216.26 Million USD
Based on the latest financial reports, Nektar Therapeutics (NKTR) has total liabilities worth $216.26 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nektar Therapeutics - Total Liabilities Trend (1994–2024)
This chart illustrates how Nektar Therapeutics's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nektar Therapeutics Competitors by Total Liabilities
The table below lists competitors of Nektar Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
India | ₹90.06 Billion |
|
American Superconductor Corporation
NASDAQ:AMSC
|
USA | $182.70 Million |
|
Fujian Huoju Electronic
SHG:603678
|
China | CN¥2.10 Billion |
|
Vericel Corporation
F:ATQP
|
Germany | €131.42 Million |
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
China | CN¥17.69 Billion |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
Korea | ₩278.20 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down Nektar Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nektar Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nektar Therapeutics (1994–2024)
The table below shows the annual total liabilities of Nektar Therapeutics from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $243.11 Million | -8.96% |
| 2023-12-31 | $267.05 Million | -22.36% |
| 2022-12-31 | $343.96 Million | -21.41% |
| 2021-12-31 | $437.68 Million | -5.16% |
| 2020-12-31 | $461.47 Million | -19.32% |
| 2019-12-31 | $571.97 Million | +32.22% |
| 2018-12-31 | $432.60 Million | +2.75% |
| 2017-12-31 | $421.04 Million | -12.42% |
| 2016-12-31 | $480.75 Million | -3.00% |
| 2015-12-31 | $495.63 Million | +22.29% |
| 2014-12-31 | $405.29 Million | -22.72% |
| 2013-12-31 | $524.43 Million | +16.34% |
| 2012-12-31 | $450.77 Million | +10.28% |
| 2011-12-31 | $408.74 Million | -5.07% |
| 2010-12-31 | $430.56 Million | -9.00% |
| 2009-12-31 | $473.15 Million | +27.75% |
| 2008-12-31 | $370.38 Million | -27.47% |
| 2007-12-31 | $510.66 Million | -5.63% |
| 2006-12-31 | $541.12 Million | +1.76% |
| 2005-12-31 | $531.74 Million | +91.56% |
| 2004-12-31 | $277.58 Million | -38.67% |
| 2003-12-31 | $452.60 Million | +13.19% |
| 2002-12-31 | $399.87 Million | +0.74% |
| 2001-12-31 | $396.93 Million | +12.87% |
| 2000-12-31 | $351.66 Million | +150.87% |
| 1999-12-31 | $140.18 Million | +653.03% |
| 1998-12-31 | $18.61 Million | -17.88% |
| 1997-12-31 | $22.67 Million | +254.20% |
| 1996-12-31 | $6.40 Million | +113.33% |
| 1995-12-31 | $3.00 Million | +66.67% |
| 1994-12-31 | $1.80 Million | -- |